A Clinical Context Report
|
|
- Gerard Heath
- 6 years ago
- Views:
Transcription
1 Type 2 Diabetes in Practice An Expert Commentary with Silvio E. Inzucchi, MD A Clinical Context Report
2 Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and
3 Clinical Context: Type 2 Diabetes in Practice Expert Commentary This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. which was made possible, in part, through a collaboration with Eli Lilly and Company.
4 Type 2 Diabetes in Practice Clinical Context Series The goal of this series is to provide up-todate information and multiple perspectives on the pathogenesis, patient identification, symptoms, risk factors, current and emerging treatments, and best practices in the management of type 2 diabetes.
5 Type 2 Diabetes in Practice Clinical Context Series Target Audience Endocrinologists, cardiologists, diabetes educators, primary care physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care of patients with type 2 diabetes.
6 Activity Learning Objective Upon successful completion of this educational program, participants should be able to: l Review the relevance and significance of the activity in the broader context of clinical care.
7 CME Information: Physicians l Statement of Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Projects In Knowledge and MedPage Today. Projects In Knowledge is accredited by the ACCME to provide continuing medical education for physicians.
8 CME Information l Credit Designation Projects In Knowledge designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
9 CME Information: Physicians l Credit for Family Physicians MedPage Today "News-Based CME" has been reviewed and is acceptable for up to 2098 Elective credits by the American Academy of Family Physicians. AAFP accreditation begins January 1, Term of approval is for one year from this date. Each article is approved for 0.5 Elective credits. Credit may be claimed for one year from the date of each article.
10 CE Information: Nurses l Statement of Accreditation Projects In Knowledge, Inc. (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP This activity is approved for 0.50 nursing contact hours. There is no fee for this activity. DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.
11 CE Information: Pharmacists l Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This activity is worth up to 0.5 contact hours (0.05 CEUs). The ACPE Universal Activity Number assigned to this knowledge-type activity is H04-P.
12 Discussant Silvio E. Inzucchi, MD Professor of Medicine Clinical Director, Section of Endocrinology Director, Yale Diabetes Center Director, Endocrinology & Metabolism Fellowship Director, Yale Affiliated Hospitals Program New Haven, Connecticut
13 Disclosure Information Silvio Inzucchi, MD, has disclosed the following relevant financial relationships: Salary/Honoraria: Over the past 12 months, has served on advisory boards or, has consulting agreements from: Boehringer Ingelheim, Merck, and Takeda Research/Support from: Eli Lilly, and Takeda
14 Disclosure Information Dori F. Zaleznik, MD, Associate Clinical Professor of Medicine, Harvard Medical School, Boston; Kristina Fiore; and Dorothy Caputo, MA, BSN, RN, Nurse Planner, have disclosed that they have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity. The staffs of Projects In Knowledge and MedPage Today have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity.
15 ADA/EASD Guidelines for Hyperglycemia Clinicians should take an individualized, patientcentric approach to therapeutic management of type 2 diabetes 1 After metformin, no second-line agent is a clear winner 1. Inzucchi SE, et al Management of hyperglycemia in type 2 diabetes: a patientcentered approach. Position statement of the ADA and EASD
16 Individualization of Therapy Much individualization is based on adverse effects Sulfonylureas and insulin not ideal for patients at high risk of hypoglycemia TZDs not optimal for those with baseline edema or in women with osteoporosis Avoid GLP-1 agonists in patients who can t tolerate GI effects DPP-4 inhibitors have mild side effects but are less potent
17 Thiazolidinediones (TZDs) Risks still unclear Caution arose with 2007 study linking Avandia with MI 2 Actos included in ADA/EASD guidelines, appears to improve CV complications overall However, concerns remain about Actos and risks of heart failure due to fluid retention, fractures in women, and bladder cancer 2. Nissen SE, Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007; 356.
18 Early Aggressive Management Recent Lancet study found insulin as second-line agent improves glycemic control over sitagliptin 3 Patients may prefer pill over injection Most clinicians still use insulin as third-line agent 3. Achsner P, et al Insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicenter, randomized, open-label trial Lancet 2012; DOI: /S (12)
19 ACCORD - ADVANCE - VADT Trials found no cardiovascular benefits for aggressive glycemic control Caveat: trials recruited patients with advanced disease Aggressive management may improve microand macrovascular complications if done early on in disease course, but benefits may not be seen for decades
20 Attempting Early Aggressive Management Focus on lifestyle: diet and exercise alone can help significantly reduce HbA1c Metformin is the preferred first-line therapy after diet and exercise After metformin, use combination therapy with an SU, TZD, DPP-4 inhibitor, GLP-1 agonist or insulin GLP-1 agonist as third-line therapy may be as potent as insulin
21 In the Pipeline About 10 to 15 classes under investigation Many will never make it to market SGLT-2 Inhibitors: Canagliflozin Dapagliflozin (received thumbs-down from FDA advisory committee) Empagliflozin Block reabsorption of glucose by kidney Side effects: UTI, yeast infections
22 In the Pipeline (continued) Glucagon receptor agonists Glucokinase activators 11-beta-HSD inhibitors Very early in development
23 Summary At the end of this activity, participants should understand: l l l l Joint guidelines from ADA and EASD recommend a highly individualized approach to the management of type 2 diabetes. After lifestyle modification and metformin, there is no clear winner among second-line agents. Reasonable choices: sulfonylureas, TZDs, DPP-4 inhibitors, GLP-1 agonists and basal insulin Most individualization of therapy is based on the adverse effects associated with each agent.
24 Summary (cont.) Sulfonylureas and insulin should be avoided if possible in patients at high risk of hypoglycemia. TZDs are not recommended for patients who should not gain more weight, or for women with osteoporosis and those at risk of fracture Patients who cannot tolerate gastrointestinal side effects aren t the best candidates for GLP-1 agonists. DPP-4 inhibitors have milder side effects but are less potent.
25 Summary (cont.) l l l Some studies have shown that when aggressive management is started early, it may hold cardiovascular benefits further down the line. Trials that have found little benefit for early aggressive management were largely conducted in patients with advanced disease, which may skew the results. Clinicians can practice early aggressive management by strongly encouraging significant lifestyle changes when the disease is first diagnosed.
26 Summary (cont.) l l l There are several new agents coming down the pike, notably the SGLT-2 inhibitors SGLT-2s work by dumping excess glucose into the urine, which appears to up the risk of genitourinary infections. Investigational agents, such as other glucagon receptor agonists and glucokinase activators, are still very far from clinical use.
Type 2 Diabetes in Practice. An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report
Type 2 Diabetes in Practice An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and
More informationHIV/AIDS in Practice. An Expert Commentary with Myron Cohen, MD. A Clinical Context Report
HIV/AIDS in Practice An Expert Commentary with Myron Cohen, MD A Clinical Context Report Clinical Context: HIV/AIDS in Practice Expert Commentary Jointly Sponsored by: and Clinical Context: HIV/AIDS in
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationA Clinical Context Report
Rheumatoid Arthritis in Practice An Expert Commentary with Diane Horowitz, MD A Clinical Context Report Rheumatoid Arthritis in Practice Jointly Sponsored by: and Rheumatoid Arthritis in Practice Expert
More informationHIV/AIDS in Practice. An Expert Commentary with Nelson Michael, MD, PhD. A Clinical Context Report
HIV/AIDS in Practice An Expert Commentary with Nelson Michael, MD, PhD A Clinical Context Report Clinical Context: HIV/AIDS in Practice Expert Commentary Jointly Sponsored by: and Clinical Context: HIV/AIDS
More informationA Clinical Context Report
Metastatic Breast Cancer in Practice An Expert Commentary with Carey Anders, MD A Clinical Context Report Clinical Context: Metastatic Breast Cancer in Practice Expert Commentary Jointly Sponsored by:
More informationA Clinical Context Report
Non-small Cell Lung Cancer in Practice An Expert Commentary With Karen Reckamp, MD A Clinical Context Report Clinical Context: NSCLC in Practice Expert Commentary Jointly Sponsored by: and Clinical Context:
More informationA Clinical Context Report
A Look Back at 2010 HIV/AIDS Research (Part 1) Expert Commentary A Clinical Context Report A Look Back at 2010 HIV/AIDS Research (Part 1) Jointly Sponsored by: and MedPage Today A Look Back at 2010 HIV/AIDS
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationENDOCRINOLOGY FOR PRIMARY CARE: Hilton Head Island, South Carolina Hilton Head Marriott Resort & Spa August 9 12, 2018
ENDOCRINOLOGY FOR PRIMARY CARE: Hilton Head Island, South Carolina Hilton Head Marriott Resort & Spa August 9 12, 2018 Thursday, August 9th: 7:00 am 7:30 am Registration and Hot Breakfast 7:30 am 8:30
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationType 1 Diabetes: New and Emerging Therapeutic Strategies to Address Unmet Needs
A CME REGIONAL MEETING SERIES Type 1 Diabetes: New and Emerging Therapeutic Strategies to Address Unmet Needs Thursday, March 7, 2019 Halekulani Hotel Honolulu, Hawaii THIS ACTIVITY IS JOINTLY PROVIDED
More informationA Comprehensive Strategy on the Modern Management of Type 1 and Type 2 Diabetes
11 TH YEAR IN A UNIQUE NATIONAL SERIES A Comprehensive Strategy on the Modern Management of Type 1 and Type 2 Diabetes MEDICAL EDUCATION FOR HEALTHCARE PROFESSIONALS Making the Connection Between Patients
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationCLINICAL ENDOCRINOLOGY FOR PRIMARY CARE
CLINICAL ENDOCRINOLOGY FOR PRIMARY CARE Walt Disney World Resort, Florida Disney s Grand Floridian Resort & Spa November 14 16, 2014 Participating Faculty Veronica Piziak, MD, PhD Professor of Medicine
More informationENDOCRINOLOGY FOR PRIMARY CARE
ENDOCRINOLOGY FOR PRIMARY CARE Las Vegas, Nevada The Cosmopolitan February 27 March 1, 2015 Participating Faculty Gregory A. Brent, MD Professor, Departments of Medicine and Physiology David Geffen School
More informationMaking the Connection
Making the Connection Between Patients and Providers A Comprehensive Overview of the Modern Treatment Strategies For People With Type 1 and Type 2 Diabetes Saturday, May 5, 2018 Hawaii Convention Center
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationCASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
More informationMaking the Connection
Making the Connection Between Patients and Providers A Comprehensive Overview of the Modern Treatment Strategies For People With Type 1 and Type 2 Diabetes Saturday, February 3, 2018 William A. Egan Civic
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationMaking the Connection
Making the Connection Between Patients and Providers A Comprehensive Overview of the Modern Treatment Strategies For People With Type 1 and Type 2 Diabetes Saturday, March 17, 2018 Monterey Conference
More informationOral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus You should be offering psychosocial care to all patients with diabetes, says the ADA. Here are the specific recommendations. Summary Recommendation
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More information... CME/CPE QUIZ... CME/CPE QUESTIONS
CME/CPE QUESTIONS Continuing Medical Education Accreditation The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 credit hours in category 1 credit toward
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationThiazolidinedione Step Therapy Program
Thiazolidinedione Step Therapy Program Policy Number: 5.01.580 Last Review: 7/2018 Origination: 07/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationMaking the Connection Between Patients and Providers
Making the Connection Between Patients and Providers A Comprehensive Overview of the Modern Treatment Strategies For People With Type 1 and Type 2 Diabetes Saturday, April 27, 2019 Hawaii Convention Center
More informationGERIATRIC MEDICINE FOR PRIMARY CARE. Chicago, Illinois The Gwen, A Luxury Collection Hotel, Chicago June 22 24, 2018
GERIATRIC MEDICINE FOR PRIMARY CARE Chicago, Illinois The Gwen, A Luxury Collection Hotel, Chicago June 22 24, 2018 Friday, June 22nd: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Faculty
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationCARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Yosemite, California Tenaya Lodge at Yosemite September 21 23, 2018
CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE Yosemite, California Tenaya Lodge at Yosemite September 21 23, 2018 Friday, September 21st: 7:00 am 7:30 am Registration and Hot Breakfast 7:30 am 8:30 am Cardiology
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationCARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018
CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018 Friday, May 18th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationSATURDAY FEBRUARY 23, 2013
MAKING THE CONNECTION 8th 7th Year in a Unique National Series Improving Clinical Care and Adherence for Patients with Diabetes SATURDAY FEBRUARY 23, 2013 Tucson Convention Center Tucson, Arizona Continuing
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationA CME Regional Meeting Series Comparing and Contrasting Basal Insulin Strategies
A CME Regional Meeting Series Comparing and Contrasting Basal Insulin Strategies In Type 1 and Type 2 Diabetes Thursday, August 2, 2018 Sheraton Grand Sacramento, Sacramento, California TCOYD is a 501(c)3
More informationPEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: GASTROENTEROLOGY/NEUROLOGY/RHEUMATOLOGY
PEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: GASTROENTEROLOGY/NEUROLOGY/RHEUMATOLOGY Quebec City, Quebec, Canada Fairmont Le Chateau Frontenac June 22 24, 2018 Friday, June 22nd: 7:30 am 8:00 am Registration
More informationTCOYD Regional Meeting Series Comparing and Contrasting Basal Insulin Strategies
TCOYD Regional Meeting Series Comparing and Contrasting Basal Insulin Strategies In Type 1 and Type 2 Diabetes Thursday, May 17, 2018 Loews Vanderbilt Hotel Nashville, Tennessee TCOYD is a 501(c)3 nonprofit
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationWOMEN S HEALTH FOR PRIMARY CARE. San Diego, California Hotel del Coronado August 10 13, 2017
WOMEN S HEALTH FOR PRIMARY CARE San Diego, California Hotel del Coronado August 10 13, 2017 Thursday, August 10th: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Gynecology Abnormal Uterine
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationSpeaker 1 Affiliation. Speaker 2 Affiliation. Speaker 3 Affiliation
RHEUMATOLOGY AND MUSCULOSKELETALL MEDICINE FOR PRIMARY CARE New York, New York InterContinental New York Times Square April 25 27,, 2014 Participating Faculty Speaker 1 Affiliation Speaker 2 Affiliation
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationORTHOPEDIC MEDICINE FOR PRIMARY CARE: NECK & SPINE/ORTHOPEDICS. Las Vegas, Nevada Bellagio Hotel and Casino November 16 18, 2018
ORTHOPEDIC MEDICINE FOR PRIMARY CARE: NECK & SPINE/ORTHOPEDICS Las Vegas, Nevada Bellagio Hotel and Casino November 16 18, 2018 Friday, November 16th: 7:00 am 7:30 am Registration and Hot Breakfast 7:30
More informationINTERNAL MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GASTROENTEROLOGY/INFECTIOUS DISEASE/ PSYCHIATRY
INTERNAL MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GASTROENTEROLOGY/INFECTIOUS DISEASE/ PSYCHIATRY Kapolei, Oahu, Hawaii Aulani, A Disney Resort & Spa June 24 28, 2018 Sunday, June 24th: 3:30 pm 4:00 pm
More informationNEUROLOGY FOR PRIMARY CARE. Las Vegas, Nevada The Cosmopolitan May 11 13, 2018
NEUROLOGY FOR PRIMARY CARE Las Vegas, Nevada The Cosmopolitan May 11 13, 2018 Friday, May 11th: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Faculty 1 The Neurological Exam Characteristics
More informationENDOCRINOLOGY FOR PRIMARY CARE
ENDOCRINOLOGY FOR PRIMARY CARE Grand Cayman Islands, BWI The Westin Grand Cayman Seven Mile Beach Resort and Spa April 30 May 3, 2015 Participating Faculty Linda A. Barbour, MD, MSPH Professor of Medicine
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationAmylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement
More information8/12/2016. Diabetes Management Across the Spectrum of Kidney Function. Andrew Bzowyckyj. Learning Objectives. Ashley Crowl
Diabetes Management Across the Spectrum of Kidney Function Andrew Bzowyckyj PharmD, BCPS, CDE Clinical Assistant Professor School of Pharmacy University of Missouri-Kansas City Kansas City, MO Ashley Crowl
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationOLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION
OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION Biljana Parapid, MD, PhD, FESC Belgrade University School of Medicine, Belgrade (Serbia) @biljana_parapid COI International
More informationMedia Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationA Guidance Statement from the American College of Physicians
Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationGERIATRIC MEDICINE FOR PRIMARY CARE: NEUROLOGY/PALLIATIVE CARE/RHEUMATOLOGY. San Diego, California Hotel del Coronado October 26 28, 2018
GERIATRIC MEDICINE FOR PRIMARY CARE: NEUROLOGY/PALLIATIVE CARE/RHEUMATOLOGY San Diego, California Hotel del Coronado October 26 28, 2018 Friday, October 26th: 7:00 am 7:30 am Registration and Hot Breakfast
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationAn Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus
Nevada Academy of Family Physicians 29 th Annual Summer CME Meeting August 3 5, 2018 An Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus Presented by: James D. Honeycutt,
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationPEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GYNECOLOGY/INFECTIOUS DISEASE. Scottsdale, Arizona The Phoenician February 8 10, 2019
PEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GYNECOLOGY/INFECTIOUS DISEASE Scottsdale, Arizona The Phoenician February 8 10, 2019 Friday, February 8th: 7:00 am 7:30 am Registration and
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationKEY ISSUES IN INTERNAL MEDICINE FOR: EAR NOSE THROAT/GASTROENTEROLOGY/ENDOCRINOLOGY
KEY ISSUES IN INTERNAL MEDICINE FOR: EAR NOSE THROAT/GASTROENTEROLOGY/ENDOCRINOLOGY Palm Springs, California Hyatt Regency Indian Wells Resort & Spa February 20 22, 2015 Participating Faculty Cynthia Hild
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationINTERNAL MEDICINE FOR PRIMARY CARE: MEDICOLEGAL/NEUROLOGY/PALLIATIVE CARE. Yellowstone National Park/Big Sky, Montana Big Sky Resort July 6 8, 2018
INTERNAL MEDICINE FOR PRIMARY CARE: MEDICOLEGAL/NEUROLOGY/PALLIATIVE CARE Yellowstone National Park/Big Sky, Montana Big Sky Resort July 6 8, 2018 Friday, July 6th: 7:00 am 7:30 am Registration and Hot
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationSMOKING CESSATION FOR PREGNANCY AND BEYOND: A VIRTUAL CLINIC WB2590
SMOKING CESSATION FOR PREGNANCY AND BEYOND: A VIRTUAL CLINIC WB2590 PROGRAM DESCRIPTION: The goal of this educational offering is to improve the clinical application of best practice interventions for
More informationINTERNAL MEDICINE FOR PRIMARY CARE: GYNECOLOGY/MEN S UROLOGY/PAIN/PSYCHIATRY. London, United Kingdom The Savoy Hotel, London August 27 30, 2018
INTERNAL MEDICINE FOR PRIMARY CARE: GYNECOLOGY/MEN S UROLOGY/PAIN/PSYCHIATRY London, United Kingdom The Savoy Hotel, London August 27 30, 2018 Monday, August 27th: 7:00 am 7:30 am Registration and Arrival
More informationDIABETES and CANCER 2017:
Symposium on DIABETES and CANCER 2017: Novel Links and Treatments Friday, April 7, 2017 New York Academy of Medicine 1216 Fifth Avenue (at 103rd Street) 10029 Course Directors Professor of Medicine, Interim
More informationDisclosures of Interest. Publications Diabetologia Key points to emphasize
Disclosures of Interest No conflicts or disclosures How to Use the American Diabetes Association s Type 2 Diabetes Treatment Algorithm Rashida Downing, MD, FAAFP Primary Care Physician JenCare Medical
More information